DUBLIN – European biotechnology is on course for a new high-water mark in terms of equity funding, after a strong performance in the third quarter, particularly among listed firms raising additional cash. In total, European biotech firms engaged in drug development raised $2.489 billion during the third quarter, in disclosed transactions tracked by BioWorld. The sector has so far raised $6.348 billion over the first nine months of the year, which puts it on track to top $8 billion for the full year. It is already within touching distance of last year's full-year total of $6.85 billion. (See BioWorld, Jan. 8, 2018.)